[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100422116":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":51,"centralContacts":56,"locations":65,"responsibleParty":78,"collaborators":10,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":10,"enrollmentInfo":91,"targetDuration":94,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":10,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,16,20,24,28,32,36],{"label":9,"type":10,"description":11,"interventionNames":12},"MARK_AF",null,"MARKers of ATrial Remodeling in Patietns with Atrial Fibrillation. Patients with paroxysmal and persistent atrial fibrillation undergoing thoracoscopic atrial fibrillation ablation surgery",[13,14,15],"Other: Biobank for Left atrial appendage tissue","Other: Biobank for Blood","Other: Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.",{"label":17,"type":10,"description":18,"interventionNames":19},"INDICO AF","Atrial Fibrillation in Patients With an Implantable Cardioverter Defibrillator and Coronary Artery Disease. Investigate the incidence of new-onset AF in patients with coronairy artery disease and an impaired LVEF, who will receive a single chamber ICD as primary prevention for sudden cardiac death.",[14],{"label":21,"type":10,"description":22,"interventionNames":23},"PREDICT AF","PREDICT AF, Tissue, Blood and biomarkers to predict future Atrial Fibrillation. Patients without a history of atrial fibrillation undergoing cardiothoracic surgery",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"WEIGHTLOSS AF","The change of adipose tissue characteristics upon drastic weight loss: Implications for atrial fibrillation.",[14,15],{"label":29,"type":10,"description":30,"interventionNames":31},"MAD AF","(123I-mIBG And Defibrillation for Atrial Fibrillation) Enhanced sympathetic activity as a mechanism of Atrial Fibrillation. Patients will undergo 123I-mIBG scintigraphy within 7 days before and six week after an elective cardioversion is performed.",[14],{"label":33,"type":10,"description":34,"interventionNames":35},"Adapt Biobank - AF surgery","Patients with Atrial Fibrillation who only donate blood and tissue for the biobank. Patients undergo thorascopic surgery, LAA will be amputated, blood will be collected.",[13,14,15],{"label":37,"type":10,"description":38,"interventionNames":39},"Adapt Biobank - blood","Patients with cardiac arrhythmias who only donate blood for the ADAPT biobank.",[14],[41,45,48],{"type":6,"name":42,"description":43,"armGroupLabels":44,"otherNames":10},"Biobank for Left atrial appendage tissue","Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.",[33,9,21],{"type":6,"name":46,"description":43,"armGroupLabels":47,"otherNames":10},"Biobank for Blood",[33,37,17,29,9,21,25],{"type":6,"name":49,"description":43,"armGroupLabels":50,"otherNames":10},"Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.",[33,9,21,25],[52],{"name":53,"affiliation":54,"role":55},"Joris de Groot, MD, PhD","Amsterdam UMC - AMC","PRINCIPAL_INVESTIGATOR",[57,62],{"name":58,"role":59,"phone":60,"phoneExt":10,"email":61},"Elise Hulsman, Bc RN","CONTACT","31205665653","e.l.hulsman@amsterdamumc.nl",{"name":53,"role":59,"phone":63,"phoneExt":10,"email":64},"310205666555","j.r.degroot@amsterdamumc.nl",[66],{"facility":67,"status":68,"city":69,"state":10,"zip":10,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":10},"Amsterdam University Medical Center location AMC","RECRUITING","Amsterdam","Netherlands","NL",{"type":73,"coordinates":74},"Point",[75,76],4.88969,52.37403,{"lat":76,"lon":75},{"type":55,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"J.R. de Groot","Prof.dr.","100422116","biobank-for-arrhythmia-and-conduction-disorders-toward-pathophysiology-based-treatment-100422116",false,"NCT04776642","Biobank for \"Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment\"","\"Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment\" ADAPT Biobank","ADAPT","Inclusion criteria:\n\n* Patients visiting the AMC outpatient clinic\n* Patients included in an ongoing clinical trial linked to this biobank. Studies are listed under point \"Groups and interventions\" and include:\n\n  * MARK AF\n  * INDICO AF\n  * PREDICT AF\n  * WEIGHTLOSS AF\n  * MAD AF\n* Patients included in future clinical trial linked to this biobank. Studies may be linked to this biobank that investigates prevalent or incident cardiac arrhythmias.\n* Cardiac arrhtymias are defined as\n\n  * Supraventricular tachycardia, among which the most common are:\n\n    * Atrial Fibrillation (AF)\n    * Atrial Tachycardia (AT)\n    * Atrial Flutter (AFL)\n    * Atrioventricular Nodal Reentrant Tachycardia (AVNRT)\n    * Atrioventricular Reentrant Tachycardia (AVRT)\n  * Ventricular tachycardia, among which the most common are:\n\n    * Ventricular Tachycardia (VT)\n    * Ventricular Flutter (VFL)\n    * Ventricular Fibrillation (VF)\n  * Bradycardia:\n\n    * Sinus Node Dysfunction\n    * AV Node Dysfunction\n    * Interventricular Conduction Disorder\n  * Arrhythmogenic cardiomyopathies, among which the most common are:\n\n    * Dilated Cardiomyopathy\n    * Restrictive Cardiomyopathy\n    * Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)\n\nExclusion criteria (shared for all studies):\n\n* Age \\\u003C 18\n* Unable or unwilling to comply with study procedures\n* Pregnancy or of childbearing potential without adequate contraception\n* NYHA class IV heart failure symptoms or left ventricular ejection fraction \\\u003C35%.","ALL","18 Years",{"count":92,"type":93},1000,"ESTIMATED","5 Years","OBSERVATIONAL","The 'ADAPT' Biobank is a collection of body material and data from patients with or at risk of cardiac arrhythmias who underwent or will undergo (non-) invasive treatment for this disease. Its main objective is to obtain a comprehensive collection of patient information and material to facilitate research and gain better insight into the complex pathophysiology of the different arrhythmias, the multifactorial process, the heterogeneity in clinical presentation, and prognosis.\n\nBodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.",[98,99,100],"Arrythmia","Conduction Disorder","Pathophysiology","2024-01-24",{"date":103,"type":104},"2024-01-25","ACTUAL",{"date":106,"type":104},"2014-12-18",{"date":108,"type":93},"2030-01",{"name":5,"class":6},1]